Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Status Completed

Clinical Trial Summary

The purpose of this research study is to evaluate how effective ONTAK is in the treatment of cutaneous T-cell Lymphoma (CTCL) and determine whether the presence of a type of protein called CD25 on the cancer cells makes a difference in how the body responds to the treatment.

The hypothesis is that there is no difference in response rate for patients whose tumor cells are CD25 positive or negative.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00211198
Study type	Interventional
Source	Eisai Inc.
Contact
Status	Completed
Phase	Phase 4
Start date	May 2001
Completion date	January 2006

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03357224` - PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)	Phase 2
Completed	`NCT02567656` - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma	Phase 1
Completed	`NCT00051012` - Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients	Phase 4
Recruiting	`NCT03646422` - AEDV Registry of Primary Cutaneous Lymphoma
Terminated	`NCT03789864` - Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides	N/A
Active, not recruiting	`NCT04998331` - A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin
Active, not recruiting	`NCT02953301` - Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)	Phase 2
Completed	`NCT01486277` - A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma	Phase 2
Completed	`NCT01433731` - Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)	Phase 1
Completed	`NCT05137847` - A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
Active, not recruiting	`NCT03902184` - IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma	Phase 2
Completed	`NCT00896493` - Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma	Phase 2
Terminated	`NCT03601819` - Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders	Phase 1
Withdrawn	`NCT03742804` - Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma	Phase 2
Completed	`NCT02836886` - VircapSeq Virus Detection in Sézary Syndrome
Completed	`NCT00050999` - Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients	Phase 4
Terminated	`NCT02323659` - Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas	Phase 4
Recruiting	`NCT02840747` - Tissue Repository: CTCL Collection Protocol
Completed	`NCT03192202` - AFM13 in Relapsed/Refractory Cutaneous Lymphomas	Phase 1/Phase 2
Terminated	`NCT02811783` - Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL	Phase 3